Read the full stored bill text
SB1542 - 572R - I Ver
REFERENCE TITLE:
controlled substances; approval; use; research
State of Arizona
Senate
Fifty-seventh Legislature
Second Regular Session
2026
SB 1542
Introduced by
Senator
Payne
AN
ACT
Amending title 23, chapter 6, article 4,
Arizona Revised Statutes, by adding section 23-973; amending section 36-2511,
Arizona Revised Statutes, as amended by laws 2021, chapter 61, section 12;
amending section 36-2511, Arizona Revised Statutes, as amended by Laws
2025, chapter 231, section 1; amending title 36, chapter 27, article 2, Arizona
Revised Statutes, by adding section 36-2517.03; appropriating monies;
relating to controlled substances.
(TEXT OF BILL BEGINS ON NEXT PAGE)
Be it enacted by the Legislature of the State of Arizona:
Section 1. Title 23, chapter 6, article 4,
Arizona Revised Statutes, is amended by adding section 23-973, to read:
START_STATUTE
23-973.
Coverage; midomafetamine; firefighters; peace officers; post-traumatic
stress disorder; annual report; definitions
A. Employers shall provide workers'
compensation coverage to firefighters and certified peace officers who have
been diagnosed with post-traumatic stress disorder by a licensed mental
health professional and who have an accepted workers' compensation claim for
post-traumatic stress disorder under this title.� If an independent
medical examination reveals that a treatment protocol of Midomafetamine is
deemed a reasonable and necessary treatment and follows the treatment
guidelines established by the commission, workers' compensation coverage may
include one complete course of a treatment protocol of Midomafetamine as
prescribed by a psychiatrist.
B. Midomafetamine prescribed under
this section must meet the requirements under title 36, chapter 27 for a
controlled substance.
C. On or before January 1, 2029 and
each January 1 thereafter, the commission shall submit to the joint legislative
budget committee a report of the costs of treatment for Midomafetamine under
this section for firefighters and certified peace officers.
D. For the purposes of this section:
1. "Certified peace
officer" has the same meaning prescribed in section 38-842.
2. "Firefighter" means a
professional firefighter who is a member of a city, town, county or fire
district fire department.
3. "Licensed mental health
professional" means an individual who specializes in trauma and crisis,
who uses evidence-based treatment options and who is licensed as either:
(
a
) A
psychiatrist pursuant to title 32, chapter 13 or 17.
(
b
) A
psychologist pursuant to title 32, chapter 19.1.
4. "Treatment protocol of
Midomafetamine" means a process of treatment that has received approval
from the United States Food and Drug
Administration for post-traumatic stress disorder and that uses
Midomafetamine in conjunction with therapy sessions.
END_STATUTE
Sec. 2. Section 36-2511, Arizona Revised
Statutes, as amended by Laws 2021, chapter 61, section 12, is amended to read:
START_STATUTE
36-2511.
Nomenclature
The controlled substances listed or to be listed in the
schedules in sections 36-2512, 36-2513, 36-2514, 36-2515,
36-2516
,
and
36-2517
and 36-2517.03
or the rules adopted pursuant to this
article are included by whatever official, common, usual, chemical or trade
name designated.
END_STATUTE
Sec. 3. Section 36-2511, Arizona Revised Statutes, as amended by Laws 2025, chapter 231, section
1, is amended to read:
START_STATUTE
36-2511.
Nomenclature
The controlled substances listed or to be listed in the
schedules in sections 36-2512, 36-2513, 36-2514, 36-2515,
36-2516, 36-2517
,
and
36-2517.02
�and 36-2517.03
or the rules adopted pursuant to
this article are included by whatever official, common, usual, chemical or
trade name designated.
END_STATUTE
Sec. 4. Title 36, chapter 27, article 2,
Arizona Revised Statutes, is amended by adding section 36-2517.03, to read:
START_STATUTE
36-2517.03.
United States food and drug administration; approved medication;
rescheduling
Any compound, mixture or preparation that
contains 3, 4-methylenedioxymethamphetamine and that is approved by the
United States food and drug administration and rescheduled by the United States
drug enforcement administration to a schedule other than schedule I of the
controlled substances act (P.L. 91-513; 84 Stat. 1242; 21 United States
Code sections 801 through 904) is a controlled substance for the purposes of
this chapter and may be prescribed in this state.
END_STATUTE
Sec. 5.
Appropriation;
department of health services; treatment of post-traumatic stress
disorder; midomafetamine; exemption
A. The sum of $10,000,000
is appropriated from the state general fund in fiscal year 2026-2027 to
the department of health services to award grants pursuant to title 41, chapter
24, Arizona Revised Statutes, for clinical trials, applied clinical research
and training of clinicians� in the use of midomafetamine to treat post-traumatic
stress disorder and specifically the safe administration of midomafetamine to
first responders and veterans who are affected by post-traumatic stress
disorder.
B. The department may award
grants for eligible projects to one or more of the following entities:
1. A sponsor of record or
principal investigator that:
(a) Has completed at least
one late-stage clinical trial relating to the use of midomafetamine to
treat post-traumatic stress disorder.
(b) Is currently
participating in a United States food and drug administration drug review
process relating to the use of midomafetamine to treat post-traumatic
stress disorder.
2. A public institution of
higher education in this state that meets one of the following:
(a) Delivers clinical care
in the field of mental health or substance use disorders.
(b) Provides accredited
professional educational or clinical training programs in behavioral health
disciplines.
(c) Conducts clinical,
translational or implementation research related to mental health or substance
use disorder treatment.
3. A public institution of
higher education in this state described in paragraph 2 of this subsection that
serves as the lead institution on behalf of a collaborative partnership or
formal consortium formed for the purpose of carrying out an eligible project
pursuant to subsection E of this section.� The partnership or consortium shall
include the sponsor of record.
C. Each application for a
grant under this section must identify a sponsor of record that will be
responsible for regulatory compliance, product supply and safety oversight for
the eligible project.
D. The sponsor of record
described in subsection B, paragraph 1 of this section may serve as the lead
applicant, a co-applicant or a subrecipient.� An entity described in
subsection B, paragraph 2 of this section may serve as the lead applicant, and
the sponsor of record may be a co-applicant or subrecipient.
E. Each eligible project
must support at least one of the following objectives:
1. Applied clinical
research and clinical trials by conducting practice-oriented research to
evaluate and improve models of care, treatment protocols or patient outcomes
for the administration of midomafetamine to residents of this state who are
impacted by post-traumatic stress disorder, specifically veterans and
first responders who are impacted by post-traumatic stress disorder.
2. Clinical training
through the design and delivery of evidence-based training programs to
prepare health care providers in this state to safely and effectively
administer midomafetamine to treat post-traumatic stress disorder,
including veterans and first responders.
F. For any eligible project
involving the administration of midomafetamine or reliance on prior clinical
data, the application shall include documentation, which must be issued by the
sponsor of record, of both:
1. Product supply
sufficient to complete the project.
2. A right of reference or
other regulatory authorization, as applicable, to rely on United States food
and drug administration submissions relating to midomafetamine.
G. The appropriation made
in subsection A of this section is exempt from the provisions of section
35-190, Arizona Revised Statutes, relating to lapsing of appropriations.
Sec. 6.
Conditional enactment; notice; industrial
commission duties
A. Section 23-973,
Arizona Revised Statutes, as added by this act, does not become effective
unless on or before January 1, 2029 the United States food and drug
administration approves the use of midomafetamine to treat post-traumatic
stress disorder.
B. The executive director
of the Arizona state board of pharmacy shall notify the director of the Arizona
legislative council and the director of the industrial commission of Arizona in
writing on or before February 1, 2029 either:
1. Of the date on which the
condition was met.
2. That the condition was
not met.
C. On notification from the
Arizona state board of pharmacy that the condition has been met, the industrial
commission of Arizona shall assign reimbursement values in its schedule of fees
and publish guidelines on billing and reimbursement practices for
midomafetamine.
Sec. 7.
Conditional
enactments; notice
A. Section 36-2511, Arizona
Revised Statutes, as amended by Laws 2021, chapter 61, section 12 and this act,
and section 36-2517.03, Arizona Revised Statutes, as added by this act, do not
become effective unless on or before January 1, 2029 a 3, 4-methylenedioxymethamphetamine
investigational product is newly approved as a prescription medication pursuant
to 21 United States Code section 355 and is controlled under a federal interim
final rule issued pursuant to 21 United States Code section 811(j) and published
in the Federal Register.
B. Section 36-2511, Arizona
Revised Statutes, as amended by Laws 2025, chapter 231, section 1 and this act,
does not become effective unless both the condition prescribed by Laws 2025,
chapter 231, section 5, subsection A is met and on or before January 1, 2029 a
3, 4-methylenedioxymethamphetamine investigational product is newly
approved as a prescription medication pursuant to 21 United States Code section
355 and is controlled under a federal interim final rule issued pursuant to 21
United States Code section 811(j) and published in the Federal Register.
C. The executive director
of the Arizona state board of pharmacy shall notify in writing the director of
the Arizona legislative council on or before February 1, 2029 either:
1. Of the date on which the
condition was met.
2. That the condition was
not met.
Sec. 8.
Conditional enactment; notice
A. Section
5 this act does not become effective unless on or before January 1, 2027 a
midomafetamine investigational product is approved as a prescription medication
pursuant to 21 United States Code section 355 and is controlled under a federal
interim final rule issued pursuant to 21 United States Code section 811(j) and
published in the Federal Register.
B. The executive director
of the Arizona state board of pharmacy shall notify the director of the Arizona
legislative council in writing on or before February 1, 2027 either:
1. Of the date on which the
condition was met.
2. That the condition was
not met.